|
FY2026
12 months to Jan 31, 2026
|
FY2025
12 months to Jan 31, 2025
|
FY2024
12 months to Jan 31, 2024
|
FY2023
12 months to Jan 31, 2023
|
FY2022
12 months to Jan 31, 2022
|
|
|---|---|---|---|---|---|
| Net sales | |||||
| Costs of sales | |||||
| Gross profit | |||||
| Operating expenses: | |||||
| Research and development | |||||
| Selling, general and administrative | |||||
| Total operating expenses | |||||
| Income from operations | |||||
| Other income (expenses) | |||||
| Interest expense | |||||
| Interest income | |||||
| Amortization of debt discount | |||||
| Other income | |||||
| Total other expenses | |||||
| Income before income tax provision and income from equity method investment | |||||
| Income from equity method investment | |||||
| Income tax provision | |||||
| Net income | |||||
| Less: series B preferred dividends | |||||
| Net income available to common stockholders | |||||
| Net income per common share | |||||
| basic (in dollars per share) | |||||
| diluted (in dollars per share) | |||||
| Weighted average common shares outstanding | |||||
| basic (in shares) | |||||
| diluted (shares) | |||||
Loading...